Research

Gilead’s oral ulcerative colitis drug shows stronger remission rates than Entyvio

Endpoints News reported stronger remission rates than Entyvio in a Phase 2 trial, and Gilead plans late-stage trials next year.

Reported by 2 outlets Monday, October 19, 2026

Assorted colorful pills and capsules
Photo: CC0

The original reports on this story are listed below.

Reporting on this story

    More top stories

    This Week in Medicine

    The week in medicine, in five minutes

    The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

    Free. No spam. Unsubscribe anytime.